Medtech To Benefit From 20% Corporate Rate, Tax-Free Foreign Transfers In Pending US Tax Bill
Executive Summary
Medical device firms will benefit from a Republican tax bill that has passed the full US House and a key Senate committee. The bill lowers the corporate tax rate to 20% from a maximum of 35%, treats foreign-earned intangible income at a favorably low rate of 12.5%, and permits tax-free transfers of intangible corporate property, such as patents, from foreign firms to US parents.
You may also be interested in...
Orthopedic Device Firms Lobby Hard On COVID-19 Relief And Reimbursements, Among Other Issues
Firms including Depuy Synthes, Medtronic Inc., and Zimmer Biomet Holdings Inc., spent thousands of dollars lobbying Congress last winter.
Medtech's Unfinished Business For Congress In 2018: What's Ahead
US Congress successfully pushed through a user-fee bill in 2017 to help smooth the regulatory path at FDA for medical devices and other products, but other efforts, including several industry priorities, remain undone. On top on the list, of course, is the effort to repeal the device excise tax. But legislation is also on the table to address diagnostics regulation, telehealth reimbursement, and medtech cybersecurity vulnerability, among other issues. Here is a look at the medtech landscape in Congress in 2018.
Medtech Supporter Sen. Orrin Hatch To Retire At Year's End
The medtech industry will lose a champion in Congress when Senate Finance Panel Chair Orrin Hatch, R-Utah, retires at the end of the 2018 congressional session. Author of the Americans with Disabilities Act and the Children's Health Insurance Program law, Hatch has been a perennial supporter of device-tax repeal, introduced market-based pricing for lab test reimbursements, and sponsored deep cuts in taxes for corporations in tax reform legislation signed into law just last month. Might former Massachusetts governor and failed 2008 US presidential candidate Mitt Romney run for the soon-to-be vacated seat?